



Press Release

CRITICAL OUTCOME TECHNOLOGIES TO COMMENCE TRADING IN U.S. ON OTCQB UNDER SYMBOL COTQF

Enhancing investor access and awareness in the U.S. market

London, Ontario (June 16, 2014): Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX-V: COT; OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced that its common shares will commence trading today in the United States on the OTCQB venture stage marketplace under the symbol “COTQF.”

“Trading on OTCQB affirms our commitment to enhance the value of our Company by improving our visibility and exposure in the United States,” said Dr. Wayne Danter, COTI’s President & CEO. “We believe that trading on OTCQB is in the best interest of our shareholders by creating an opportunity for U.S. based investors to obtain information about the Company and invest through a trading platform familiar to them. While we continue to appreciate the loyalty and support of our Canadian investor base, we feel that the Company has reached an important inflection point in its growth that requires us to open ourselves up to the larger, and more life science-focused, U.S. market. This improved access is expected to foster increased interest in the Company and improve liquidity for all investors.”

OTCQB offers investors transparent trading in early-stage and developing U.S. and international companies. To be eligible, companies must meet a minimum \$0.01 bid test, be current in their reporting and undergo an annual verification and management certification process. International companies must also be listed on a qualified foreign stock exchange and receive a Letter of Introduction from a Principal American Liaison (“PAL”), which must be a qualified third-party investment bank, securities law firm or depositary bank.

U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for COTI on www.otcmarkets.com.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI’s proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.

Dr. Wayne Danter

President & CEO

Tel: 519-858-5157

Email: wdanter@criticaloutcome.com

Heisler Communications

Trevor Heisler

Investor Relations

Tel: 416-500-8061

Email: trevor@heislercommunications.com

U.S. Contact:

Robert Giordano

Office: 212-257-5495

Mobile: 917-327-3938

E-mail: rgiordano@jstreichercapital.com

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

Notice to Readers

Information contained in this press release may contain certain statements, which constitute “forward-looking statements” within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statement “... This improved access is expected to foster increased interest in the Company and improve liquidity for all investors.” is a forward-looking statement. Forward-looking statements by their nature are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.